Users of this system, can login to view this document.

Login

Enter the following information to request a copy of the document from the responsible person.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.

This email address is used for sending the document.